Item 4, purpose of the transaction:Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: This Amendment No. 5 is being filed to report the acquisition of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent f…Read the filing
Madrigal Pharmaceuticals, Inc. MDGL
Institutional owners are on their way
13F data can be up to 45 days oldWe read every 13F filing after each quarter ends. The owners of MDGL show here after the next update.
Institutional ownership
Institutional owners
Institutional owners are on their wayWe read every 13F filing after each quarter ends. The owners of MDGL show here after the next update.
Funds that hold MDGL
Mutual funds and ETFs, each from its own latest portfolio report. Funds report on their own quarter ends.
Fund holdings are on their wayWe read the funds' N-PORT reports after each quarter. The funds that hold MDGL show here after the next update.
Superinvestors holding MDGL
The investors followed on Tickdelta, from their latest 13F.
None of the followed investors held MDGL in their latest 13F.
13D filings: owners who may push for change
Owners of more than 5%
Item 4, purpose of the transaction:No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer.Read the filing
Item 4, purpose of the transaction:No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.Read the filing
Sources
SEC's Form 13F data sets, each quarter; Form N-PORT data sets for the funds; Schedule 13D filings.
Also
Investors: the portfolios of the superinvestors followed here. Insider trades: what the company's own people bought and sold.